Novartis Licenses Preclinical Radioligand Asset From BoomRay

Company BoomRay Pharmaceuticals / Novartis Event Type Exclusive Global License Modality Radioligand Therapy Asset Undisclosed Preclinical Radioligand Therapy Target Undisclosed Disease Area Undisclosed (Oncology, Presumed) Summary Suzhou-based BoomRay granted Novartis exclusive global rights to an undisclosed preclinical radioligand therapy asset. BoomRay is eligible for up…